Millennium Over-Delivers on 2007 Goals and Financia...(immunofixation-negative complete remissi...)

percent with MP. Preliminary results showed that at 16 months

follow-up, VcMP significantly reduced the risk of death in

patients by 40 percent with median survival not yet reached.

-- IFM (Intergroupe Francophone du Myelome) cooperative group -- In

482 patients, the combination of VELCADE and dexamethasone (VcD)

demonstrated a significantly higher immunofixation-negative and

positive complete remission rate of 21 percent, compared to eight

percent with vincristine, adriamycin and dexamethasone (VAD), a

commonly used induction therapy prior to SCT. The VELCADE based

induction regimen enhanced post SCT outcomes for patients by

achieving a significantly higher immunofixation-negative and

positive complete remission rate of 41 percent compared to 29

percent with VAD.

-- GIMEMA (Italian Myeloma Network) cooperative group -- The

combination of VELCADE, thalidomide, and dexamethasone (VcTD), as

induction therapy prior to SCT, showed a dramatic fourfold

increase in complete remission rate when compared to thalidomide

and dexamethasone (TD), the most commonly used induction regimen

in the U.S. for patients eligible for SCT. These results from 256

patients prior to SCT showed a 36 percent immunofixation-negative

and positive complete remission rate for VcTD compared to nine

percent for TD. Once again, the VELCADE based induction regimen

enhanced post SCT outcomes for patients by achieving a

significantly higher immunofixation-negative and positive complete

remission rate of 57 percent compared to 28 percent for TD.

-- The safety profile in these Phase III s
'/>"/>